Labcorp Finalizes Acquisition of Select Assets of Invitae

On August 5, 2024 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company (Press release, Invitae, AUG 5, 2024, View Source [SID1234645339]). Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, patient diagnosis and personalized care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Labcorp and Invitae are on a shared mission to harness the power of genetic insights to transform medicine, deliver personalized care and improve health outcomes," said Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer of Labcorp. "By adding Invitae’s cutting edge science and industry-leading experience, we will extend our leadership in genetic testing solutions with the most comprehensive offerings in areas such as oncology and select rare diseases. We are excited to welcome Invitae’s talented team to Labcorp and look forward to bringing genetic testing solutions to patients and physicians to improve health and improve lives."

The acquisition expands Labcorp’s specialty testing capabilities and the company’s ability to utilize genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases. By integrating Invitae’s genetic testing technology with Labcorp’s specialty testing capabilities, the company will offer a more complete set of insights for each patient – from testing to diagnosis to treatment.

For more information visit Labcorp.com/invitae.

Invitae is advised by Kirkland & Ellis LLP as legal counsel, Moelis & Company LLC as investment banker and FTI Consulting, Inc. as financial and communications advisor. Citi is serving as Labcorp’s financial advisor and Hogan Lovells and Kilpatrick Townsend are serving as Labcorp’s legal counsel.